Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879737 | 0.84 | ROCK2 (0.65) | ROCK2METCYP3A4 | |
| SCHEMBL31554522 | 0.84 | ROCK2 (0.65) | ROCK2METCYP3A4 | |
| SCHEMBL4819441 | 0.83 | AXL (0.49) | ROCK2AXLPRKCIMET | |
| Hydrochloric Acid SCHEMBL5097103 | 0.83 | ROCK2 (0.64) | ROCK2METCYP3A4 | |
| SCHEMBL4819121 | 0.81 | IKBKB (0.52) | ROCK2AXLPRKCIMET | |
| SCHEMBL24885851 | 0.81 | ROCK2 (0.49) | ROCK2METCYP3A4 | |
| SCHEMBL31290944 | 0.81 | ROCK2 (0.49) | ROCK2METCYP3A4 | |
| SCHEMBL25793147 | 0.81 | ROCK2 (0.53) | ROCK2METCYP3A4 | |
| SCHEMBL29837329 | 0.81 | ROCK2 (0.53) | ROCK2METCYP3A4 | |
| SCHEMBL3484554 | 0.79 | KMT2A (0.52) | ROCK2AXLPRKCIMETCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | claimed |
| CN-117843567-A | Diazaaryl ring substituted benzene derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ROCK2 395/4885AXL 452/4885PRKCI 25/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | ROCK2 433/4885AXL 880/4885PRKCI 22/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ROCK2 395/4885AXL 452/4885PRKCI 25/4885 |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | ROCK2 648/4885AXL 131/4885PRKCI 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.